Progenics Pharmaceuticals, Inc.  

(Public, NASDAQ:PGNX)   Watch this stock  
Find more results for PGNX
5.98
+0.16 (2.75%)
After Hours: 5.98 0.00 (0.00%)
Mar 31, 4:39PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 5.79 - 6.06
52 week 3.10 - 7.84
Open 5.80
Vol / Avg. 974,866.00/1.02M
Mkt cap 415.73M
P/E 458.24
Div/yield     -
EPS 0.01
Shares 69.64M
Beta 1.72
Inst. own 89%
May 7, 2015
Q1 2015 Progenics Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Mar 16, 2015
Q4 2014 Progenics Pharmaceuticals Inc Earnings Release
Mar 16, 2015
Q4 2014 Progenics Pharmaceuticals Inc Earnings Call - Webcast
Feb 24, 2015
Progenics Pharmaceuticals Inc at RBC Healthcare Conference
Feb 10, 2015
Progenics Pharmaceuticals Inc at Biotechnology Industry Organization CEO & Investor Conference
Jan 12, 2015
Progenics Pharmaceuticals Inc at JPMorgan Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin - 9.94%
Operating margin - 7.59%
EBITD margin - 14.85%
Return on average assets -29.33% 3.20%
Return on average equity -37.47% 4.33%
Employees 57 -
CDP Score - -

Address

777 Old Saw Mill River Road
TARRYTOWN, NY 10591
United States - Map
+1-914-7892800 (Phone)
+1-914-7892817 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Progenics Pharmaceuticals, Inc. is a medicine developing company. The Company is engaged in developing medicines for oncology. Its focus for Progenics is targeted therapeutics and imaging agents. The Company�s clinical development efforts center on late-stage oncology assets. Its principal clinical-stage product candidates in oncology are PSMA ADC, 1404 (trofolastat) and Azedra. The Company�s product, Relistor, is a treatment for opioid-induced constipation (OIC). PSMA ADC is a human monoclonal antibody-drug conjugate designed to deliver a chemotherapeutic agent to cancer cells by targeting the three-dimensional structure of the PSMA protein. 1404 (trofolastat) is a radio-labeled small molecule, which binds PSMA and acts as an imaging agent to diagnose and detect prostate cancer. Azedra is a Phase 2 radiotherapeutic product candidate in development as a treatment for pheochromocytoma.

Officers and directors

Peter J. Crowley Independent Chairman of the Board
Age: 56
Bio & Compensation  - Reuters
Mark R. Baker J.D. Chief Executive Officer, Director
Age: 58
Bio & Compensation  - Reuters
Robert J. Israel M.D. Executive Vice President - Medical Affairs
Age: 57
Bio & Compensation  - Reuters
John W. Babich Ph.D. Senior Vice President
Age: 56
Bio & Compensation  - Reuters
Nitya G. Ray Ph.D. Senior Vice President - Manufacturing
Age: 61
Bio & Compensation  - Reuters
Vivien Wong Ph.D. Senior Vice President - Operations and Portfolio Management
Age: 57
Bio & Compensation  - Reuters
Angelo W. Lovallo Jr., CPA Vice President - Finance, Treasurer
Age: 48
Bio & Compensation  - Reuters
Ann Marie Assumma Vice President - Regulatory Affairs
Age: 60
Bio & Compensation  - Reuters
David E. Martin J.D. General Counsel
Age: 59
Bio & Compensation  - Reuters
Karen J. Ferrante M.D. Independent Director
Age: 56
Bio & Compensation  - Reuters